Global Intravenous Immunoglobulin (IVIg) Market

Intravenous Immunoglobulin (IVIg) Comprehensive Study by Type (Gammagard S/D, Gammagard Liquid, Gamunex, IGIVnex, Privigen, Others), Application (Neurology, Haematology, Immunology, Dermatology, Other), Treatment (Myositis, Lupus, Vasculitis, Antiphospholipid Syndrome, Others) Players and Region - Global Market Outlook to 2030

Intravenous Immunoglobulin (IVIg) Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 52.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Intravenous Immunoglobulin (IVIg)
Immunoglobulins are the antibodies produced naturally by the body’s immune system, which help fight infection and disease. Intravenous immunoglobulin (IVIg) is a treatment that syndicates immunoglobulins donated by different people and is given by a drip to treat various conditions. Intravenous immunoglobulin (IVIG) replacement therapy has greatly reduced the morbidity due to bacterial infections related with main forms of antibody deficiency. There has been a rapid growth in the use of IVIG. It has had a major impact in the treatment of conditions in the fields of neurology, haematology, rheumatology and dermatology.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR52.5%


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Intravenous Immunoglobulin (IVIg) market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Baxter international Inc. (United States), CSL Ltd. (Australia), Grifols S.A (Spain), Octapharma AG (Switzerland), Kedrion Biopharma Inc. (United States), Biotest AG (Germany), Takeda Pharmaceuticals (Japan), Hualan Biological Engineering Inc. (United States), Option Care Enterprises, Inc. (United States) and BioScrip, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Omrix Biopharmaceuticals Ltd. (Israel), ADMA Biologics, Inc. (United States) and Shanghai RAAS Blood Products Co., Ltd. (China).

Segmentation Overview
AMA Research has segmented the market of Global Intravenous Immunoglobulin (IVIg) market by Type (Gammagard S/D, Gammagard Liquid, Gamunex, IGIVnex, Privigen and Others), Application (Neurology, Haematology, Immunology, Dermatology and Other) and Region.



On the basis of geography, the market of Intravenous Immunoglobulin (IVIg) has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by , the sub-segment i.e. will boost the Intravenous Immunoglobulin (IVIg) market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Improved Techniques for Purification and Increasing Incidences of Kawasaki Disease in Children

Market Growth Drivers:
Increasing Number of Hemophilic Patients and Growing Use of Off-Label Indications

Challenges:
Neurological Disorders Associated With Immunoglobulin Treatment

Restraints:
High Risk of Side Effects

Opportunities:
Growing Awareness Related To Autoimmune Diseases and Increase in Investments in Research and Development of Novel Products

Market Leaders and their expansionary development strategies

In January 2024 CSL Behring, a business unit of global biotechnology leader CSL, today announced the availability of a 10g prefilled syringe for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid). The Hizentra prefilled syringes provide people living with Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) the ability to elevate their treatment experience by eliminating the need to draw medication from vials.


Key Target Audience
Suppliers of Pharmaceuticals, Wholesalers, Distributors and Retailers of Pharmaceuticals, Healthcare Sector, Research Organization and Governmental Bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Gammagard S/D
  • Gammagard Liquid
  • Gamunex
  • IGIVnex
  • Privigen
  • Others
By Application
  • Neurology
  • Haematology
  • Immunology
  • Dermatology
  • Other
By Treatment
  • Myositis
  • Lupus
  • Vasculitis
  • Antiphospholipid Syndrome
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Hemophilic Patients
      • 3.2.2. Growing Use of Off-Label Indications
    • 3.3. Market Challenges
      • 3.3.1. Neurological Disorders Associated With Immunoglobulin Treatment
    • 3.4. Market Trends
      • 3.4.1. Improved Techniques for Purification
      • 3.4.2. Increasing Incidences of Kawasaki Disease in Children
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Intravenous Immunoglobulin (IVIg), by Type, Application, Treatment and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Intravenous Immunoglobulin (IVIg) (Value)
      • 5.2.1. Global Intravenous Immunoglobulin (IVIg) by: Type (Value)
        • 5.2.1.1. Gammagard S/D
        • 5.2.1.2. Gammagard Liquid
        • 5.2.1.3. Gamunex
        • 5.2.1.4. IGIVnex
        • 5.2.1.5. Privigen
        • 5.2.1.6. Others
      • 5.2.2. Global Intravenous Immunoglobulin (IVIg) by: Application (Value)
        • 5.2.2.1. Neurology
        • 5.2.2.2. Haematology
        • 5.2.2.3. Immunology
        • 5.2.2.4. Dermatology
        • 5.2.2.5. Other
      • 5.2.3. Global Intravenous Immunoglobulin (IVIg) by: Treatment (Value)
        • 5.2.3.1. Myositis
        • 5.2.3.2. Lupus
        • 5.2.3.3. Vasculitis
        • 5.2.3.4. Antiphospholipid Syndrome
        • 5.2.3.5. Others
      • 5.2.4. Global Intravenous Immunoglobulin (IVIg) Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Intravenous Immunoglobulin (IVIg) (Volume)
      • 5.3.1. Global Intravenous Immunoglobulin (IVIg) by: Type (Volume)
        • 5.3.1.1. Gammagard S/D
        • 5.3.1.2. Gammagard Liquid
        • 5.3.1.3. Gamunex
        • 5.3.1.4. IGIVnex
        • 5.3.1.5. Privigen
        • 5.3.1.6. Others
      • 5.3.2. Global Intravenous Immunoglobulin (IVIg) by: Application (Volume)
        • 5.3.2.1. Neurology
        • 5.3.2.2. Haematology
        • 5.3.2.3. Immunology
        • 5.3.2.4. Dermatology
        • 5.3.2.5. Other
      • 5.3.3. Global Intravenous Immunoglobulin (IVIg) by: Treatment (Volume)
        • 5.3.3.1. Myositis
        • 5.3.3.2. Lupus
        • 5.3.3.3. Vasculitis
        • 5.3.3.4. Antiphospholipid Syndrome
        • 5.3.3.5. Others
      • 5.3.4. Global Intravenous Immunoglobulin (IVIg) Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Intravenous Immunoglobulin (IVIg) (Price)
      • 5.4.1. Global Intravenous Immunoglobulin (IVIg) by: Type (Price)
  • 6. Intravenous Immunoglobulin (IVIg): Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Baxter international Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CSL Ltd. (Australia)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Grifols S.A (Spain)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Octapharma AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Kedrion Biopharma Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biotest AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takeda Pharmaceuticals (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hualan Biological Engineering Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Option Care Enterprises, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. BioScrip, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Intravenous Immunoglobulin (IVIg) Sale, by Type, Application, Treatment and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Intravenous Immunoglobulin (IVIg) (Value)
      • 7.2.1. Global Intravenous Immunoglobulin (IVIg) by: Type (Value)
        • 7.2.1.1. Gammagard S/D
        • 7.2.1.2. Gammagard Liquid
        • 7.2.1.3. Gamunex
        • 7.2.1.4. IGIVnex
        • 7.2.1.5. Privigen
        • 7.2.1.6. Others
      • 7.2.2. Global Intravenous Immunoglobulin (IVIg) by: Application (Value)
        • 7.2.2.1. Neurology
        • 7.2.2.2. Haematology
        • 7.2.2.3. Immunology
        • 7.2.2.4. Dermatology
        • 7.2.2.5. Other
      • 7.2.3. Global Intravenous Immunoglobulin (IVIg) by: Treatment (Value)
        • 7.2.3.1. Myositis
        • 7.2.3.2. Lupus
        • 7.2.3.3. Vasculitis
        • 7.2.3.4. Antiphospholipid Syndrome
        • 7.2.3.5. Others
      • 7.2.4. Global Intravenous Immunoglobulin (IVIg) Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Intravenous Immunoglobulin (IVIg) (Volume)
      • 7.3.1. Global Intravenous Immunoglobulin (IVIg) by: Type (Volume)
        • 7.3.1.1. Gammagard S/D
        • 7.3.1.2. Gammagard Liquid
        • 7.3.1.3. Gamunex
        • 7.3.1.4. IGIVnex
        • 7.3.1.5. Privigen
        • 7.3.1.6. Others
      • 7.3.2. Global Intravenous Immunoglobulin (IVIg) by: Application (Volume)
        • 7.3.2.1. Neurology
        • 7.3.2.2. Haematology
        • 7.3.2.3. Immunology
        • 7.3.2.4. Dermatology
        • 7.3.2.5. Other
      • 7.3.3. Global Intravenous Immunoglobulin (IVIg) by: Treatment (Volume)
        • 7.3.3.1. Myositis
        • 7.3.3.2. Lupus
        • 7.3.3.3. Vasculitis
        • 7.3.3.4. Antiphospholipid Syndrome
        • 7.3.3.5. Others
      • 7.3.4. Global Intravenous Immunoglobulin (IVIg) Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Intravenous Immunoglobulin (IVIg) (Price)
      • 7.4.1. Global Intravenous Immunoglobulin (IVIg) by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Intravenous Immunoglobulin (IVIg): by Type(USD Million)
  • Table 2. Intravenous Immunoglobulin (IVIg) Gammagard S/D , by Region USD Million (2018-2023)
  • Table 3. Intravenous Immunoglobulin (IVIg) Gammagard Liquid , by Region USD Million (2018-2023)
  • Table 4. Intravenous Immunoglobulin (IVIg) Gamunex , by Region USD Million (2018-2023)
  • Table 5. Intravenous Immunoglobulin (IVIg) IGIVnex , by Region USD Million (2018-2023)
  • Table 6. Intravenous Immunoglobulin (IVIg) Privigen , by Region USD Million (2018-2023)
  • Table 7. Intravenous Immunoglobulin (IVIg) Others , by Region USD Million (2018-2023)
  • Table 8. Intravenous Immunoglobulin (IVIg): by Application(USD Million)
  • Table 9. Intravenous Immunoglobulin (IVIg) Neurology , by Region USD Million (2018-2023)
  • Table 10. Intravenous Immunoglobulin (IVIg) Haematology , by Region USD Million (2018-2023)
  • Table 11. Intravenous Immunoglobulin (IVIg) Immunology , by Region USD Million (2018-2023)
  • Table 12. Intravenous Immunoglobulin (IVIg) Dermatology , by Region USD Million (2018-2023)
  • Table 13. Intravenous Immunoglobulin (IVIg) Other , by Region USD Million (2018-2023)
  • Table 14. Intravenous Immunoglobulin (IVIg): by Treatment(USD Million)
  • Table 15. Intravenous Immunoglobulin (IVIg) Myositis , by Region USD Million (2018-2023)
  • Table 16. Intravenous Immunoglobulin (IVIg) Lupus , by Region USD Million (2018-2023)
  • Table 17. Intravenous Immunoglobulin (IVIg) Vasculitis , by Region USD Million (2018-2023)
  • Table 18. Intravenous Immunoglobulin (IVIg) Antiphospholipid Syndrome , by Region USD Million (2018-2023)
  • Table 19. Intravenous Immunoglobulin (IVIg) Others , by Region USD Million (2018-2023)
  • Table 20. South America Intravenous Immunoglobulin (IVIg), by Country USD Million (2018-2023)
  • Table 21. South America Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 22. South America Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 23. South America Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 24. Brazil Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 25. Brazil Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 26. Brazil Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 27. Argentina Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 28. Argentina Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 29. Argentina Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 30. Rest of South America Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 31. Rest of South America Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 32. Rest of South America Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 33. Asia Pacific Intravenous Immunoglobulin (IVIg), by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 35. Asia Pacific Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 36. Asia Pacific Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 37. China Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 38. China Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 39. China Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 40. Japan Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 41. Japan Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 42. Japan Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 43. India Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 44. India Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 45. India Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 46. South Korea Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 47. South Korea Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 48. South Korea Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 49. Taiwan Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 50. Taiwan Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 51. Taiwan Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 52. Australia Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 53. Australia Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 54. Australia Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 56. Rest of Asia-Pacific Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 57. Rest of Asia-Pacific Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 58. Europe Intravenous Immunoglobulin (IVIg), by Country USD Million (2018-2023)
  • Table 59. Europe Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 60. Europe Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 61. Europe Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 62. Germany Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 63. Germany Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 64. Germany Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 65. France Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 66. France Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 67. France Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 68. Italy Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 69. Italy Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 70. Italy Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 71. United Kingdom Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 72. United Kingdom Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 73. United Kingdom Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 74. Netherlands Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 75. Netherlands Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 76. Netherlands Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 77. Rest of Europe Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 78. Rest of Europe Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 79. Rest of Europe Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 80. MEA Intravenous Immunoglobulin (IVIg), by Country USD Million (2018-2023)
  • Table 81. MEA Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 82. MEA Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 83. MEA Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 84. Middle East Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 85. Middle East Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 86. Middle East Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 87. Africa Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 88. Africa Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 89. Africa Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 90. North America Intravenous Immunoglobulin (IVIg), by Country USD Million (2018-2023)
  • Table 91. North America Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 92. North America Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 93. North America Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 94. United States Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 95. United States Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 96. United States Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 97. Canada Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 98. Canada Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 99. Canada Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 100. Mexico Intravenous Immunoglobulin (IVIg), by Type USD Million (2018-2023)
  • Table 101. Mexico Intravenous Immunoglobulin (IVIg), by Application USD Million (2018-2023)
  • Table 102. Mexico Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2018-2023)
  • Table 103. Intravenous Immunoglobulin (IVIg) Sales: by Type(Litres)
  • Table 104. Intravenous Immunoglobulin (IVIg) Sales Gammagard S/D , by Region Litres (2018-2023)
  • Table 105. Intravenous Immunoglobulin (IVIg) Sales Gammagard Liquid , by Region Litres (2018-2023)
  • Table 106. Intravenous Immunoglobulin (IVIg) Sales Gamunex , by Region Litres (2018-2023)
  • Table 107. Intravenous Immunoglobulin (IVIg) Sales IGIVnex , by Region Litres (2018-2023)
  • Table 108. Intravenous Immunoglobulin (IVIg) Sales Privigen , by Region Litres (2018-2023)
  • Table 109. Intravenous Immunoglobulin (IVIg) Sales Others , by Region Litres (2018-2023)
  • Table 110. Intravenous Immunoglobulin (IVIg) Sales: by Application(Litres)
  • Table 111. Intravenous Immunoglobulin (IVIg) Sales Neurology , by Region Litres (2018-2023)
  • Table 112. Intravenous Immunoglobulin (IVIg) Sales Haematology , by Region Litres (2018-2023)
  • Table 113. Intravenous Immunoglobulin (IVIg) Sales Immunology , by Region Litres (2018-2023)
  • Table 114. Intravenous Immunoglobulin (IVIg) Sales Dermatology , by Region Litres (2018-2023)
  • Table 115. Intravenous Immunoglobulin (IVIg) Sales Other , by Region Litres (2018-2023)
  • Table 116. Intravenous Immunoglobulin (IVIg) Sales: by Treatment(Litres)
  • Table 117. Intravenous Immunoglobulin (IVIg) Sales Myositis , by Region Litres (2018-2023)
  • Table 118. Intravenous Immunoglobulin (IVIg) Sales Lupus , by Region Litres (2018-2023)
  • Table 119. Intravenous Immunoglobulin (IVIg) Sales Vasculitis , by Region Litres (2018-2023)
  • Table 120. Intravenous Immunoglobulin (IVIg) Sales Antiphospholipid Syndrome , by Region Litres (2018-2023)
  • Table 121. Intravenous Immunoglobulin (IVIg) Sales Others , by Region Litres (2018-2023)
  • Table 122. South America Intravenous Immunoglobulin (IVIg) Sales, by Country Litres (2018-2023)
  • Table 123. South America Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 124. South America Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 125. South America Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 126. Brazil Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 127. Brazil Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 128. Brazil Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 129. Argentina Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 130. Argentina Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 131. Argentina Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 132. Rest of South America Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 133. Rest of South America Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 134. Rest of South America Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 135. Asia Pacific Intravenous Immunoglobulin (IVIg) Sales, by Country Litres (2018-2023)
  • Table 136. Asia Pacific Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 137. Asia Pacific Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 138. Asia Pacific Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 139. China Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 140. China Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 141. China Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 142. Japan Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 143. Japan Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 144. Japan Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 145. India Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 146. India Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 147. India Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 148. South Korea Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 149. South Korea Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 150. South Korea Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 151. Taiwan Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 152. Taiwan Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 153. Taiwan Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 154. Australia Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 155. Australia Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 156. Australia Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 157. Rest of Asia-Pacific Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 158. Rest of Asia-Pacific Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 159. Rest of Asia-Pacific Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 160. Europe Intravenous Immunoglobulin (IVIg) Sales, by Country Litres (2018-2023)
  • Table 161. Europe Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 162. Europe Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 163. Europe Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 164. Germany Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 165. Germany Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 166. Germany Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 167. France Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 168. France Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 169. France Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 170. Italy Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 171. Italy Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 172. Italy Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 173. United Kingdom Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 174. United Kingdom Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 175. United Kingdom Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 176. Netherlands Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 177. Netherlands Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 178. Netherlands Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 179. Rest of Europe Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 180. Rest of Europe Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 181. Rest of Europe Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 182. MEA Intravenous Immunoglobulin (IVIg) Sales, by Country Litres (2018-2023)
  • Table 183. MEA Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 184. MEA Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 185. MEA Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 186. Middle East Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 187. Middle East Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 188. Middle East Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 189. Africa Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 190. Africa Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 191. Africa Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 192. North America Intravenous Immunoglobulin (IVIg) Sales, by Country Litres (2018-2023)
  • Table 193. North America Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 194. North America Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 195. North America Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 196. United States Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 197. United States Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 198. United States Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 199. Canada Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 200. Canada Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 201. Canada Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 202. Mexico Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2018-2023)
  • Table 203. Mexico Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2018-2023)
  • Table 204. Mexico Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2018-2023)
  • Table 205. Intravenous Immunoglobulin (IVIg): by Type(USD/Units)
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Company Basic Information, Sales Area and Its Competitors
  • Table 213. Company Basic Information, Sales Area and Its Competitors
  • Table 214. Company Basic Information, Sales Area and Its Competitors
  • Table 215. Company Basic Information, Sales Area and Its Competitors
  • Table 216. Intravenous Immunoglobulin (IVIg): by Type(USD Million)
  • Table 217. Intravenous Immunoglobulin (IVIg) Gammagard S/D , by Region USD Million (2025-2030)
  • Table 218. Intravenous Immunoglobulin (IVIg) Gammagard Liquid , by Region USD Million (2025-2030)
  • Table 219. Intravenous Immunoglobulin (IVIg) Gamunex , by Region USD Million (2025-2030)
  • Table 220. Intravenous Immunoglobulin (IVIg) IGIVnex , by Region USD Million (2025-2030)
  • Table 221. Intravenous Immunoglobulin (IVIg) Privigen , by Region USD Million (2025-2030)
  • Table 222. Intravenous Immunoglobulin (IVIg) Others , by Region USD Million (2025-2030)
  • Table 223. Intravenous Immunoglobulin (IVIg): by Application(USD Million)
  • Table 224. Intravenous Immunoglobulin (IVIg) Neurology , by Region USD Million (2025-2030)
  • Table 225. Intravenous Immunoglobulin (IVIg) Haematology , by Region USD Million (2025-2030)
  • Table 226. Intravenous Immunoglobulin (IVIg) Immunology , by Region USD Million (2025-2030)
  • Table 227. Intravenous Immunoglobulin (IVIg) Dermatology , by Region USD Million (2025-2030)
  • Table 228. Intravenous Immunoglobulin (IVIg) Other , by Region USD Million (2025-2030)
  • Table 229. Intravenous Immunoglobulin (IVIg): by Treatment(USD Million)
  • Table 230. Intravenous Immunoglobulin (IVIg) Myositis , by Region USD Million (2025-2030)
  • Table 231. Intravenous Immunoglobulin (IVIg) Lupus , by Region USD Million (2025-2030)
  • Table 232. Intravenous Immunoglobulin (IVIg) Vasculitis , by Region USD Million (2025-2030)
  • Table 233. Intravenous Immunoglobulin (IVIg) Antiphospholipid Syndrome , by Region USD Million (2025-2030)
  • Table 234. Intravenous Immunoglobulin (IVIg) Others , by Region USD Million (2025-2030)
  • Table 235. South America Intravenous Immunoglobulin (IVIg), by Country USD Million (2025-2030)
  • Table 236. South America Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 237. South America Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 238. South America Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 239. Brazil Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 240. Brazil Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 241. Brazil Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 242. Argentina Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 243. Argentina Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 244. Argentina Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 245. Rest of South America Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 246. Rest of South America Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 247. Rest of South America Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 248. Asia Pacific Intravenous Immunoglobulin (IVIg), by Country USD Million (2025-2030)
  • Table 249. Asia Pacific Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 250. Asia Pacific Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 251. Asia Pacific Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 252. China Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 253. China Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 254. China Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 255. Japan Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 256. Japan Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 257. Japan Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 258. India Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 259. India Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 260. India Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 261. South Korea Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 262. South Korea Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 263. South Korea Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 264. Taiwan Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 265. Taiwan Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 266. Taiwan Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 267. Australia Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 268. Australia Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 269. Australia Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 270. Rest of Asia-Pacific Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 271. Rest of Asia-Pacific Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 272. Rest of Asia-Pacific Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 273. Europe Intravenous Immunoglobulin (IVIg), by Country USD Million (2025-2030)
  • Table 274. Europe Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 275. Europe Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 276. Europe Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 277. Germany Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 278. Germany Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 279. Germany Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 280. France Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 281. France Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 282. France Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 283. Italy Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 284. Italy Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 285. Italy Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 286. United Kingdom Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 287. United Kingdom Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 288. United Kingdom Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 289. Netherlands Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 290. Netherlands Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 291. Netherlands Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 292. Rest of Europe Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 293. Rest of Europe Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 294. Rest of Europe Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 295. MEA Intravenous Immunoglobulin (IVIg), by Country USD Million (2025-2030)
  • Table 296. MEA Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 297. MEA Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 298. MEA Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 299. Middle East Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 300. Middle East Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 301. Middle East Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 302. Africa Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 303. Africa Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 304. Africa Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 305. North America Intravenous Immunoglobulin (IVIg), by Country USD Million (2025-2030)
  • Table 306. North America Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 307. North America Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 308. North America Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 309. United States Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 310. United States Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 311. United States Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 312. Canada Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 313. Canada Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 314. Canada Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 315. Mexico Intravenous Immunoglobulin (IVIg), by Type USD Million (2025-2030)
  • Table 316. Mexico Intravenous Immunoglobulin (IVIg), by Application USD Million (2025-2030)
  • Table 317. Mexico Intravenous Immunoglobulin (IVIg), by Treatment USD Million (2025-2030)
  • Table 318. Intravenous Immunoglobulin (IVIg) Sales: by Type(Litres)
  • Table 319. Intravenous Immunoglobulin (IVIg) Sales Gammagard S/D , by Region Litres (2025-2030)
  • Table 320. Intravenous Immunoglobulin (IVIg) Sales Gammagard Liquid , by Region Litres (2025-2030)
  • Table 321. Intravenous Immunoglobulin (IVIg) Sales Gamunex , by Region Litres (2025-2030)
  • Table 322. Intravenous Immunoglobulin (IVIg) Sales IGIVnex , by Region Litres (2025-2030)
  • Table 323. Intravenous Immunoglobulin (IVIg) Sales Privigen , by Region Litres (2025-2030)
  • Table 324. Intravenous Immunoglobulin (IVIg) Sales Others , by Region Litres (2025-2030)
  • Table 325. Intravenous Immunoglobulin (IVIg) Sales: by Application(Litres)
  • Table 326. Intravenous Immunoglobulin (IVIg) Sales Neurology , by Region Litres (2025-2030)
  • Table 327. Intravenous Immunoglobulin (IVIg) Sales Haematology , by Region Litres (2025-2030)
  • Table 328. Intravenous Immunoglobulin (IVIg) Sales Immunology , by Region Litres (2025-2030)
  • Table 329. Intravenous Immunoglobulin (IVIg) Sales Dermatology , by Region Litres (2025-2030)
  • Table 330. Intravenous Immunoglobulin (IVIg) Sales Other , by Region Litres (2025-2030)
  • Table 331. Intravenous Immunoglobulin (IVIg) Sales: by Treatment(Litres)
  • Table 332. Intravenous Immunoglobulin (IVIg) Sales Myositis , by Region Litres (2025-2030)
  • Table 333. Intravenous Immunoglobulin (IVIg) Sales Lupus , by Region Litres (2025-2030)
  • Table 334. Intravenous Immunoglobulin (IVIg) Sales Vasculitis , by Region Litres (2025-2030)
  • Table 335. Intravenous Immunoglobulin (IVIg) Sales Antiphospholipid Syndrome , by Region Litres (2025-2030)
  • Table 336. Intravenous Immunoglobulin (IVIg) Sales Others , by Region Litres (2025-2030)
  • Table 337. South America Intravenous Immunoglobulin (IVIg) Sales, by Country Litres (2025-2030)
  • Table 338. South America Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 339. South America Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 340. South America Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 341. Brazil Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 342. Brazil Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 343. Brazil Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 344. Argentina Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 345. Argentina Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 346. Argentina Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 347. Rest of South America Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 348. Rest of South America Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 349. Rest of South America Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 350. Asia Pacific Intravenous Immunoglobulin (IVIg) Sales, by Country Litres (2025-2030)
  • Table 351. Asia Pacific Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 352. Asia Pacific Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 353. Asia Pacific Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 354. China Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 355. China Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 356. China Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 357. Japan Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 358. Japan Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 359. Japan Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 360. India Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 361. India Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 362. India Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 363. South Korea Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 364. South Korea Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 365. South Korea Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 366. Taiwan Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 367. Taiwan Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 368. Taiwan Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 369. Australia Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 370. Australia Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 371. Australia Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 372. Rest of Asia-Pacific Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 373. Rest of Asia-Pacific Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 374. Rest of Asia-Pacific Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 375. Europe Intravenous Immunoglobulin (IVIg) Sales, by Country Litres (2025-2030)
  • Table 376. Europe Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 377. Europe Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 378. Europe Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 379. Germany Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 380. Germany Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 381. Germany Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 382. France Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 383. France Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 384. France Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 385. Italy Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 386. Italy Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 387. Italy Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 388. United Kingdom Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 389. United Kingdom Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 390. United Kingdom Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 391. Netherlands Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 392. Netherlands Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 393. Netherlands Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 394. Rest of Europe Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 395. Rest of Europe Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 396. Rest of Europe Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 397. MEA Intravenous Immunoglobulin (IVIg) Sales, by Country Litres (2025-2030)
  • Table 398. MEA Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 399. MEA Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 400. MEA Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 401. Middle East Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 402. Middle East Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 403. Middle East Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 404. Africa Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 405. Africa Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 406. Africa Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 407. North America Intravenous Immunoglobulin (IVIg) Sales, by Country Litres (2025-2030)
  • Table 408. North America Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 409. North America Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 410. North America Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 411. United States Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 412. United States Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 413. United States Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 414. Canada Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 415. Canada Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 416. Canada Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 417. Mexico Intravenous Immunoglobulin (IVIg) Sales, by Type Litres (2025-2030)
  • Table 418. Mexico Intravenous Immunoglobulin (IVIg) Sales, by Application Litres (2025-2030)
  • Table 419. Mexico Intravenous Immunoglobulin (IVIg) Sales, by Treatment Litres (2025-2030)
  • Table 420. Intravenous Immunoglobulin (IVIg): by Type(USD/Units)
  • Table 421. Research Programs/Design for This Report
  • Table 422. Key Data Information from Secondary Sources
  • Table 423. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Intravenous Immunoglobulin (IVIg): by Type USD Million (2018-2023)
  • Figure 5. Global Intravenous Immunoglobulin (IVIg): by Application USD Million (2018-2023)
  • Figure 6. Global Intravenous Immunoglobulin (IVIg): by Treatment USD Million (2018-2023)
  • Figure 7. South America Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 8. Asia Pacific Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 9. Europe Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 10. MEA Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 11. North America Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 12. Global Intravenous Immunoglobulin (IVIg): by Type Litres (2018-2023)
  • Figure 13. Global Intravenous Immunoglobulin (IVIg): by Application Litres (2018-2023)
  • Figure 14. Global Intravenous Immunoglobulin (IVIg): by Treatment Litres (2018-2023)
  • Figure 15. South America Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 16. Asia Pacific Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 17. Europe Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 18. MEA Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 19. North America Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 20. Global Intravenous Immunoglobulin (IVIg): by Type USD/Units (2018-2023)
  • Figure 21. Global Intravenous Immunoglobulin (IVIg) share by Players 2023 (%)
  • Figure 22. Global Intravenous Immunoglobulin (IVIg) share by Players (Top 3) 2023(%)
  • Figure 23. Global Intravenous Immunoglobulin (IVIg) share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Baxter international Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Baxter international Inc. (United States) Revenue: by Geography 2023
  • Figure 27. CSL Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 28. CSL Ltd. (Australia) Revenue: by Geography 2023
  • Figure 29. Grifols S.A (Spain) Revenue, Net Income and Gross profit
  • Figure 30. Grifols S.A (Spain) Revenue: by Geography 2023
  • Figure 31. Octapharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Octapharma AG (Switzerland) Revenue: by Geography 2023
  • Figure 33. Kedrion Biopharma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Kedrion Biopharma Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Biotest AG (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Biotest AG (Germany) Revenue: by Geography 2023
  • Figure 37. Takeda Pharmaceuticals (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Takeda Pharmaceuticals (Japan) Revenue: by Geography 2023
  • Figure 39. Hualan Biological Engineering Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Hualan Biological Engineering Inc. (United States) Revenue: by Geography 2023
  • Figure 41. Option Care Enterprises, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Option Care Enterprises, Inc. (United States) Revenue: by Geography 2023
  • Figure 43. BioScrip, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. BioScrip, Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Global Intravenous Immunoglobulin (IVIg): by Type USD Million (2025-2030)
  • Figure 46. Global Intravenous Immunoglobulin (IVIg): by Application USD Million (2025-2030)
  • Figure 47. Global Intravenous Immunoglobulin (IVIg): by Treatment USD Million (2025-2030)
  • Figure 48. South America Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 49. Asia Pacific Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 50. Europe Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 51. MEA Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 52. North America Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 53. Global Intravenous Immunoglobulin (IVIg): by Type Litres (2025-2030)
  • Figure 54. Global Intravenous Immunoglobulin (IVIg): by Application Litres (2025-2030)
  • Figure 55. Global Intravenous Immunoglobulin (IVIg): by Treatment Litres (2025-2030)
  • Figure 56. South America Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 57. Asia Pacific Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 58. Europe Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 59. MEA Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 60. North America Intravenous Immunoglobulin (IVIg) Share (%), by Country
  • Figure 61. Global Intravenous Immunoglobulin (IVIg): by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Baxter international Inc. (United States)
  • CSL Ltd. (Australia)
  • Grifols S.A (Spain)
  • Octapharma AG (Switzerland)
  • Kedrion Biopharma Inc. (United States)
  • Biotest AG (Germany)
  • Takeda Pharmaceuticals (Japan)
  • Hualan Biological Engineering Inc. (United States)
  • Option Care Enterprises, Inc. (United States)
  • BioScrip, Inc. (United States)
Additional players considered in the study are as follows:
Omrix Biopharmaceuticals Ltd. (Israel) , ADMA Biologics, Inc. (United States) , Shanghai RAAS Blood Products Co., Ltd. (China)
Select User Access Type

Key Highlights of Report


Mar 2024 235 Pages 77 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Intravenous Immunoglobulin (IVIg) Market Quantitative research analysis
Global Intravenous Immunoglobulin (IVIg) Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Baxter international Inc. (United States), CSL Ltd. (Australia), Grifols S.A (Spain), Octapharma AG (Switzerland), Kedrion Biopharma Inc. (United States), Biotest AG (Germany), Takeda Pharmaceuticals (Japan), Hualan Biological Engineering Inc. (United States), Option Care Enterprises, Inc. (United States) and BioScrip, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Improved Techniques for Purification " is seen as one of major influencing trends for Intravenous Immunoglobulin (IVIg) Market during projected period 2023-2030.
The Intravenous Immunoglobulin (IVIg) market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Intravenous Immunoglobulin (IVIg) Market Report?

Have a Query? Click Here

Other Related Reports

Fondaparinux Comprehensive Study by Type (Branded, Generic), Application (Home Care Settings, Hip/Knee Replacement, Cardiovascular, Abdominal Surgery, Other), Sales Channel (Third-Party Website, Manu...
$ 3650
Oxcarbazepine Drug Comprehensive Study by Type (Oxcarbazepine Tablet, Oral suspension), Application (Adult, Pediatric), Dosage (150 mg, 300 mg, 600 mg) Players and Region - Global Market Outlook to 2...
$ 3500
Traditional Chinese Medicine Comprehensive Study by Type (Chinese Herbal Medicine, Acupuncture, Tai Chi, Cupping, Moxibustion, Others), Distribution Channel (Hospitals & Clinics, Retail Pharmacies, O...
$ 3800
Tylosin Tartrate Comprehensive Study by Type (Powder, Particles), Application (Veterinary Hospital, Farmers, Others), Treatment Groups (Full Dose (200mg), Half Dose(100 mg), Sugar treated control), ...
$ 3750
Cannabidiol (CBD) Comprehensive Study by Application (Personal Care & Cosmetics, Pharmaceutical, Food & Beverages, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores...
$ 3650
Retinal Drugs Comprehensive Study by Type (Wet AMD, Diabetic Retinopathy, DME, RVO, Mcnv), Prescription Type (Prescription Ophthalmic Drugs, OTC), Distribution Channel (Hospital Pharmacies, Drug Stor...
$ 3350